EGFR and non-small cell lung carcinoma: In NSCLC patients with EGFR-WT who relapsed after one or more first-line therapies, the combination of AFM24 and atezolizumab led to 1 complete response, 3 partial responses, and 7 cases of stable disease among the 15 evaluable patients (120).